Mission Produce Beats Q3 Estimates, Raises Calavo Savings Outlook to Over $30 Million
Fiscal Q3 showed $450 million in sales and $32.4 million adjusted EBITDA.
Already have an account? Sign in.
Fiscal Q3 showed $450 million in sales and $32.4 million adjusted EBITDA.
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.
Strong fuel margins helped Casey’s beat earnings. Slower grocery and in-store sales, plus no guidance raise, sparked the selloff.
The company will not advance the drug in eczema and shifts focus to EVO301.